Cidara Therapeutics (CDTX) Competitors $62.82 -2.03 (-3.13%) Closing price 04:00 PM EasternExtended Trading$62.75 -0.07 (-0.11%) As of 06:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CDTX vs. ADMA, KRYS, AKRO, RNA, PTCT, ACLX, MRUS, ZLAB, SRRK, and ACADShould you be buying Cidara Therapeutics stock or one of its competitors? The main competitors of Cidara Therapeutics include ADMA Biologics (ADMA), Krystal Biotech (KRYS), Akero Therapeutics (AKRO), Avidity Biosciences (RNA), PTC Therapeutics (PTCT), Arcellx (ACLX), Merus (MRUS), Zai Lab (ZLAB), Scholar Rock (SRRK), and ACADIA Pharmaceuticals (ACAD). These companies are all part of the "pharmaceutical products" industry. Cidara Therapeutics vs. Its Competitors ADMA Biologics Krystal Biotech Akero Therapeutics Avidity Biosciences PTC Therapeutics Arcellx Merus Zai Lab Scholar Rock ACADIA Pharmaceuticals Cidara Therapeutics (NASDAQ:CDTX) and ADMA Biologics (NASDAQ:ADMA) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and media sentiment. Does the media prefer CDTX or ADMA? In the previous week, ADMA Biologics had 5 more articles in the media than Cidara Therapeutics. MarketBeat recorded 8 mentions for ADMA Biologics and 3 mentions for Cidara Therapeutics. ADMA Biologics' average media sentiment score of 1.29 beat Cidara Therapeutics' score of 0.00 indicating that ADMA Biologics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cidara Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ADMA Biologics 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals have more ownership in CDTX or ADMA? 35.8% of Cidara Therapeutics shares are owned by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are owned by institutional investors. 3.9% of Cidara Therapeutics shares are owned by company insiders. Comparatively, 3.5% of ADMA Biologics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has better earnings and valuation, CDTX or ADMA? ADMA Biologics has higher revenue and earnings than Cidara Therapeutics. Cidara Therapeutics is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCidara Therapeutics$1.27M997.21-$169.83M-$29.47-2.13ADMA Biologics$426.45M9.69$197.67M$0.8520.36 Which has more volatility & risk, CDTX or ADMA? Cidara Therapeutics has a beta of 1.14, indicating that its share price is 14% more volatile than the S&P 500. Comparatively, ADMA Biologics has a beta of 0.43, indicating that its share price is 57% less volatile than the S&P 500. Do analysts rate CDTX or ADMA? Cidara Therapeutics currently has a consensus target price of $57.29, suggesting a potential downside of 8.81%. ADMA Biologics has a consensus target price of $27.67, suggesting a potential upside of 59.83%. Given ADMA Biologics' stronger consensus rating and higher possible upside, analysts clearly believe ADMA Biologics is more favorable than Cidara Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cidara Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11ADMA Biologics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Is CDTX or ADMA more profitable? ADMA Biologics has a net margin of 45.01% compared to Cidara Therapeutics' net margin of 0.00%. ADMA Biologics' return on equity of 47.16% beat Cidara Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cidara TherapeuticsN/A -73.04% -54.28% ADMA Biologics 45.01%47.16%30.51% SummaryADMA Biologics beats Cidara Therapeutics on 12 of the 16 factors compared between the two stocks. Get Cidara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CDTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CDTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CDTX vs. The Competition Export to ExcelMetricCidara TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.31B$3.06B$5.70B$9.48BDividend YieldN/A2.37%4.59%3.99%P/E Ratio-2.138.3320.9817.21Price / Sales997.21321.08443.32103.11Price / CashN/A43.2336.5558.97Price / Book4.218.308.635.90Net Income-$169.83M-$55.19M$3.24B$258.42M7 Day Performance11.88%5.07%3.22%1.94%1 Month Performance34.12%17.61%10.72%12.02%1 Year Performance430.13%7.03%34.94%20.80% Cidara Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CDTXCidara Therapeutics3.1097 of 5 stars$62.82-3.1%$57.29-8.8%+464.9%$1.31B$1.27M-2.1390ADMAADMA Biologics3.7843 of 5 stars$18.68+0.9%$27.67+48.1%+25.0%$4.46B$426.45M21.98530News CoveragePositive NewsKRYSKrystal Biotech4.8809 of 5 stars$150.41+1.5%$213.75+42.1%-26.0%$4.35B$290.52M36.16210Analyst ForecastAKROAkero Therapeutics3.7959 of 5 stars$52.73+2.2%$82.50+56.5%+86.5%$4.20BN/A-27.0430Positive NewsRNAAvidity Biosciences2.4518 of 5 stars$33.57+6.7%$66.35+97.7%-26.2%$4.05B$8.93M-11.19190News CoverageHigh Trading VolumePTCTPTC Therapeutics4.4237 of 5 stars$49.46+1.9%$65.00+31.4%+40.3%$3.92B$806.78M7.601,410ACLXArcellx2.603 of 5 stars$69.92+1.4%$111.23+59.1%+10.8%$3.85B$76.81M-23.3880News CoveragePositive NewsMRUSMerus2.0858 of 5 stars$55.62+2.1%$84.64+52.2%+15.5%$3.85B$36.13M-13.6337Upcoming EarningsZLABZai Lab3.4779 of 5 stars$34.28+4.7%$54.28+58.3%+92.7%$3.81B$398.99M-13.771,869Positive NewsGap UpSRRKScholar Rock3.3951 of 5 stars$38.59+3.1%$42.67+10.6%+331.6%$3.66B$33.19M-15.25140Analyst RevisionACADACADIA Pharmaceuticals4.2561 of 5 stars$21.89+4.3%$27.88+27.3%+27.9%$3.66B$957.80M15.98510Positive NewsAnalyst Forecast Related Companies and Tools Related Companies ADMA Biologics Competitors Krystal Biotech Competitors Akero Therapeutics Competitors Avidity Biosciences Competitors PTC Therapeutics Competitors Arcellx Competitors Merus Competitors Zai Lab Competitors Scholar Rock Competitors ACADIA Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CDTX) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredElon Just Fired the IRS Agents Targeting Your SavingsElon Musk just fired 6,700 IRS agents — and exposed a war on your retirement. While D.C. scrambles to regai...Priority Gold | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cidara Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cidara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
